Changing focus in diabetes: From glucose to cardiovascular risk management.

27 August 2018 (13:05 - 13:35)

Organised by:

About the speaker

Professor Stephan Jacob

Villingen (Germany)

4 More presentations in this session

Presentation thumbnail

Introduction - Targeting SGLT2 in clinical cardiology: exploring the benefits in cardiovascular risk, diabetes & heart failure.

Professor F. Cosentino (Stockholm, SE)

Presentation thumbnail

SGLT2 inhibition in cardiology: what is the profile of benefit? .

Professor N. Marx (Aachen, DE)

Presentation thumbnail

Heart failure & SGLT2: with or without diabetes?

Professor J. McMurray (Glasgow, GB)

Presentation thumbnail

Discussion - Targeting SGLT2 in clinical cardiology: exploring the benefits in cardiovascular risk, diabetes & heart failure.

Professor F. Cosentino (Stockholm, SE)

Access the full session

Session thumbnail

Targeting SGLT2 in clinical cardiology: exploring the benefits in cardiovascular risk, diabetes & heart failure (EBAC Accredited)

The Event

ESC Congress 2018

27 August 2018 13:05 CET

You may be interested in

Webinar

EAPC Webinar: Type 2 Diabetes and cardiovascular risk

12 March 2019

Congress Presentation

Non-invasive continuous glucose monitoring in patients without diabetes: use in cardiovascular prevention - a systematic review

3 April 2025

Congress Presentation

Glucose lowering drugs or strategies, major adverse cardiovascular events and heart failure outcomes, and association with weight loss - meta-analysis of large cardiovascular outcome trials

2 September 2019

Congress Presentation

Type 2 diabetes, chronic kidney disease and major cardiovascular events in patients with established coronary artery disease

27 August 2021

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources